Microsatellite Instability-High (MSI-H) Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Microsatellite Instability-High (MSI-H) Colorectal Cancer Market Outlook

Thelansis’s “Microsatellite Instability-High (MSI-H) Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microsatellite Instability-High (MSI-H) Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Microsatellite Instability-High (MSI-H) Colorectal Cancer Overview

Microsatellite instability-high (MSI-H) colorectal cancer is a molecularly distinct colorectal cancer subtype characterised by deficient mismatch repair protein expression, resulting in widespread frameshift mutations across repetitive microsatellite DNA sequences, generating a hypermutated, highly immunogenic tumour microenvironment with abundant tumour-infiltrating lymphocytes. MSI-H tumours arise either sporadically through MLH1 promoter hypermethylation or hereditarily through germline mismatch repair gene mutations constituting Lynch syndrome, the most common hereditary colorectal cancer syndrome. Patients present with symptoms of colorectal cancer including altered bowel habits, rectal bleeding, abdominal pain, and iron deficiency anaemia, with MSI-H tumours demonstrating a predilection for right-sided, poorly differentiated, and mucinous histology. Universal tumour mismatch repair immunohistochemistry and MSI testing is recommended for all colorectal cancers, with germline testing confirming Lynch syndrome in deficient cases. MSI-H status confers profound predictive significance; immune checkpoint inhibitors deliver remarkable and durable responses, with pembrolizumab established as first-line standard of care in metastatic MSI-H colorectal cancer, and nivolumab with or without ipilimumab providing effective alternatives. Critically, MSI-H tumours are inherently resistant to fluorouracil-based chemotherapy, making molecular testing essential before treatment initiation. Surgical resection, adjuvant chemotherapy considerations, and Lynch syndrome surveillance protocols guide localised disease management. Prognosis is markedly more favourable than microsatellite stable disease in the metastatic setting with immunotherapy; genetic counselling and cascade family screening are indispensable for Lynch syndrome-associated cases.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Microsatellite Instability-High (MSI-H) Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035